Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2013 | 03-2012 | |
| Operating Expenses | 1,019 | 942 |
| Operating Income | -1,019 | -942 |
| Interest Expense | 26 | 0 |
| Pre-tax Income | -1,045 | -942 |
| Net Income Continuous | -1,045 | -942 |
| Net Income | $-1,045 | $-942 |
| EPS Basic Total Ops | -0.40 | -0.36 |
| EPS Diluted Total Ops | -0.40 | -0.36 |
| EBITDA(a) | $-1,019 | $-942 |